Stockscreener 앱 받기
254.69
9.08%
-25.43
전일 마감가:
$280.12
열려 있는:
$261.69
하루 거래량:
679.78K
Relative Volume:
2.22
시가총액:
$6.87B
수익:
$2.58B
순이익/손실:
$759.90M
주가수익비율:
9.1232
EPS:
27.9168
순현금흐름:
$374.60M
1주 성능:
-11.52%
1개월 성능:
-8.50%
6개월 성능:
-20.30%
1년 성능:
+5.93%
1일 변동 폭
$242.28
$264.22
1주일 범위
$242.28
$294.05
52주 변동 폭
$211.43
$343.12
Bio Rad Laboratories Inc Stock (BIO) Company Profile
명칭
Bio Rad Laboratories Inc
전화
(510) 724-7000
주소
1000 ALFRED NOBEL DRIVE, HERCULES
Compare BIO vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BIO
Bio Rad Laboratories Inc
|
254.54 | 7.54B | 2.58B | 759.90M | 374.60M | 27.92 |
ABT
Abbott Laboratories
|
89.81 | 163.10B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
298.62 | 123.10B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
80.48 | 105.15B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
56.86 | 86.87B | 20.62B | 3.56B | 3.66B | 2.3847 |
EW
Edwards Lifesciences Corp
|
84.44 | 47.44B | 6.30B | 1.07B | 1.34B | 1.8406 |
Bio Rad Laboratories Inc Stock (BIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-07 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-10-01 | 업그레이드 | Citigroup | Neutral → Buy |
| 2024-08-28 | 개시 | Wells Fargo | Equal Weight |
| 2024-06-03 | 재개 | Jefferies | Hold |
| 2024-04-03 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-12-07 | 개시 | UBS | Buy |
| 2023-06-16 | 개시 | Wells Fargo | Overweight |
| 2022-12-07 | 개시 | RBC Capital Mkts | Outperform |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-01-28 | 재확인 | Citigroup | Buy |
| 2020-01-08 | 개시 | Wells Fargo | Overweight |
| 2020-01-07 | 개시 | Citigroup | Buy |
| 2018-10-17 | 개시 | Goldman | Buy |
| 2018-09-20 | 개시 | Morgan Stanley | Equal-Weight |
| 2018-02-16 | 다운그레이드 | CL King | Buy → Neutral |
| 2017-07-13 | 개시 | Wells Fargo | Outperform |
| 2017-06-28 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2017-01-18 | 개시 | Deutsche Bank | Hold |
| 2016-10-13 | 개시 | CL King | Buy |
| 2015-05-06 | 재확인 | Jefferies | Buy |
| 2009-12-18 | 개시 | Maxim Group | Buy |
| 2009-11-06 | 개시 | Jefferies & Co | Buy |
| 2009-07-17 | 개시 | Soleil | Buy |
| 2007-09-26 | 개시 | Banc of America Sec | Buy |
| 2007-02-23 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
모두보기
Bio Rad Laboratories Inc 주식(BIO)의 최신 뉴스
Bio-Rad outlines 2026 currency-neutral revenue growth of -3% to +0.5% amid Middle East disruption - MSN
Bio-Rad Laboratories Q1 2026 Earnings Call Transcript - MarketBeat
Bio-Rad Laboratories Inc (BIO) Q1 2026 Earnings Call Highlights: Navigating Challenges with Strategic Growth - GuruFocus
Bio-Rad Laboratories Q1 Earnings Call Highlights - Yahoo Finance
BIO SWOT Analysis: Financial Challenges and Growth Potential Rev - GuruFocus
Bio-Rad's Timing for Revenue Growth Recovery Remains Uncertain - Morningstar
MSN Money - MSN
Bio-Rad (BIO) Reports Strong Q1 Revenue Amidst Market Challenges - GuruFocus
Bio-Rad Q1 2026 slides: earnings beat masks currency headwinds - Investing.com
Bio-Rad Laboratories (BIO) Lags Q1 Earnings Estimates - Yahoo Finance
Bio-Rad (BIO) Q1 2026: Non-GAAP EPS $1.89 (miss vs $2.81), Reven - GuruFocus
Bio-Rad Laboratories Reports Q1 2026 Results, Cuts Outlook - TipRanks
Transcript: Bio-Rad Laboratories Q1 2026 Earnings Conference Call - Benzinga
Bio-Rad Laboratories (BIO) Releases Q1 2026 Earnings: Revenue Up Slightly, EPS Deeply Negative on Large GAAP Loss - Quiver Quantitative
Bio-Rad Laboratories Q1 Adjusted Earnings Fall, Revenue Rises - marketscreener.com
Bio-Rad: Q1 Earnings Snapshot - KTVB
Liquidity Mapping Around (BIO) Price Events - Stock Traders Daily
Huge Sartorius loss drives Bio-Rad (NYSE: BIO) Q1 2026 net loss - Stock Titan
Bio-Rad (NYSE: BIO) posts Q1 loss and trims 2026 guidance - Stock Titan
Bio-Rad Reports First-Quarter 2026 Financial Results - Business Wire
Bio-Rad earnings on deck: Can margin recovery offset academic headwinds? - Investing.com Australia
Bio-Rad earnings on deck: Can margins recover after rough 2025? - Investing.com Canada
Food Diagnostics Market to Reach USD 32.8 Billion by 2033 at 9.0% - openPR.com
Transcriptomics Technologies Market to Reach USD 20.64 Billion - openPR.com
Bio-Rad launches PTC Harmony 96 and PTC Harmony Deepwell Thermal Cyclers - News-Medical
Bio-Rad (NYSE: BIO) CFO nets more shares after RSU vesting and tax withholding - Stock Titan
Bio-Rad (BIO) EVP Courtney Enloe gains shares via RSU vesting, withholds for taxes - Stock Titan
Saudi Arabia In-Vitro Diagnostics (IVD) Market Report - GlobeNewswire
Saudi Arabia In-Vitro Diagnostics (IVD) Market Report 2025-2034 Featuring Roche, Danaher, Abbott Laboratories, Thermo Fischer Scientific, Bio-Rad Laboratories, Sysmex, BD & Co, and Biomerieux - Yahoo Finance
Bio-Rad Laboratories, Inc. (BIO) Stock Analysis: A Closer Look at the Healthcare Innovator’s Growth Potential - DirectorsTalk Interviews
Citigroup downgrades Bio-Rad Laboratories (BIO) - MSN
Bio-Rad Laboratories, Inc. Amends 2017 Incentive Award Plan and Updates Entity Information in April 2026 8-K Filing - Minichart
Bio-Rad Laboratories (BIO.US) will release its earnings report after the market closes on April 30. - Moomoo
Bio-Rad Laboratories Stockholders Approve Directors and Governance Items - TipRanks
Shareholders of Bio-Rad (NYSE: BIO) approve 2017 incentive plan changes - Stock Titan
Bio-Rad Laboratories, Inc. (BIO) PT Reduced to $300 by Citigroup Amid Process Chromatography Concerns - Yahoo Finance
Bio-Rad Laboratories Inc (BIO) Shares Fall 6.4% -- What GF Score of 77 Tells Investors - GuruFocus
Greg K. Hinckley adds Bio-Rad (BIO) shares through RSU vesting and grant - Stock Titan
Bio-Rad (NYSE: BIO) director exercises 407 RSUs and receives 369-unit grant - Stock Titan
Bio-Rad (NYSE: BIO) director exercises 407 RSUs and gains 369 new units - Stock Titan
Bio-Rad (BIO) director Arnold Pinkston gains shares, receives new RSU grant - Stock Titan
9 Most Undervalued Healthcare Stocks to Buy Now - Insider Monkey
Electroporation Instruments Market is expected to Hit US$ - openPR.com
Bio-Rad Laboratories (BIO) to Release Quarterly Earnings on Thursday - MarketBeat
Boston Trust Walden Corp Lowers Stock Holdings in Bio-Rad Laboratories, Inc. $BIO - MarketBeat
Bio-Rad Laboratories (NYSE:BIO.B) Shares Gap UpHere's Why - MarketBeat
DNA Extraction, Isolation and Purification Market: Key Players - openPR.com
Metagenomics Market Key Companies AnalysisMerck KGaA, Thermo - openPR.com
Digital PCR Market Set for Strong Growth to US$ 1.45 Billion - openPR.com
Cell Identification Technology Market Is Going to Boom Rapidly | - openPR.com
dPCR Market Will Generate Booming Growth Opportunities to 2031 | - openPR.com
Bio Rad Laboratories Inc (BIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.70%
0.55%
자본화:
|
볼륨(24시간):